Resveratrol — Stack & Timing
Educational timing and stacking information based on how Resveratrol has been studied. Not a prescription. Not medical advice.
This is educational information only. Consult a healthcare provider before starting any supplement.
Stack & Timing Guidance
Educational summary based on how Resveratrol has been studied and commonly used.
Commonly studied timing
Resveratrol is fat-soluble and absorption may be improved when taken with a meal containing dietary fat; morning dosing with food is a common clinical trial protocol, though optimal timing has not been definitively established.
Dose ranges used in studies
Clinical trials have used a wide range of doses, from approximately 150 mg/day in metabolic studies to 1000 mg/day in some RCTs; bioavailability of standard resveratrol is limited, and some experts suggest methylated analogs like pterostilbene may offer superior absorption.
↑ These are ranges from research studies, not personal dosing recommendations. Discuss with a clinician.
Commonly paired with
Both are polyphenols with complementary antioxidant and anti-inflammatory mechanisms; often combined to potentially enhance synergistic effects on oxidative stress and metabolic health.
Pterostilbene is a methylated analog of resveratrol with reportedly better bioavailability and longer half-life; some experts, including Rhonda Patrick, prefer it over resveratrol or combine them for broader coverage.
Combined use may provide complementary cardiovascular and anti-inflammatory benefits; fat co-ingestion may also improve resveratrol absorption.
Resveratrol is proposed to activate sirtuins (SIRT1), which are NAD+-dependent enzymes; combining with NAD+ precursors is theorized to enhance this pathway relevant to metabolic and longevity biology.
Safety & interactions
Resveratrol is generally considered safe at studied doses in short-term trials; high doses may cause gastrointestinal discomfort. Its estrogenic properties warrant caution in hormone-sensitive conditions. Long-term safety data in humans remains limited.
- •May interact with anticoagulants (e.g., warfarin, direct oral anticoagulants) by inhibiting CYP enzymes, potentially altering drug metabolism and increasing bleeding risk.
- •May inhibit CYP3A4 and other cytochrome P450 enzymes, potentially affecting metabolism of a range of medications.
- •Potential additive effects with other antiplatelet or blood-thinning supplements or medications.
Individuals on anticoagulant or antiplatelet therapy should use caution and consult a healthcare provider. Those with hormone-sensitive conditions (e.g., estrogen receptor-positive cancers, endometriosis) should exercise caution given resveratrol's phytoestrogenic activity. Pregnant and breastfeeding individuals should avoid use due to insufficient safety data.